Specific immunotherapy in asthma: A comprehensive review

Journal of Asthma

Volumn 51, Issue 1, 2014, Pages 29-33

  Passalacqua, Giovanni ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Adverse events; Allergic asthma; Allergic rhinitis; Efficacy; Safety; Subcutaneous immunotherapy; Sublingual immunotherapy

Indexed keywords

ADD ON THERAPY; ALLERGIC RHINITIS; ASTHMA; CLINICAL TRIAL (TOPIC); GENETIC HETEROGENEITY; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; LUNG FUNCTION; META ANALYSIS; POLLEN ALLERGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FUNCTION; REVIEW; RHINITIS; RISK FACTOR; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; SYSTEMATIC REVIEW; TREATMENT DURATION;

ADMINISTRATION, SUBLINGUAL; ASTHMA; DESENSITIZATION, IMMUNOLOGIC; HUMANS; INJECTIONS, SUBCUTANEOUS; RHINITIS, ALLERGIC, PERENNIAL;

EID: 84893128549     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2013.853082     Document Type: Review

References (62)

1. WHO Position Paper. Allergen immunotherapy: Therapeutical vaccines for allergic diseases. Allergy 1998;54:1-33
2. Cox L. Allergen immunotherapy and asthma: Efficacy, safety, and other considerations. Allergy Asthma Proc 2008;29:580-589
3. Cruz AA, Popov T, Pawankar R, Annesi-Maesano I, Fokkens W, Kemp J, Ohta K, Price D, et al. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN. Allergy 2007;62:1-41
4. Bousquet PJ, Brozek J, Bachert C, Bieber T, Bonini S, Burney P, Calderon M, Canonica GW, et al. The CONSORT statement checklist in allergen-specific immunotherapy: A GA2LEN paper. Allergy 2009;64:1737-1745
5. Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ, Passalacqua G, Potter P, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007;62:317-324
6. Passalacqua G, Canonica GW. Specific immunotherapy in asthma. Efficacy and safety. Clin Exp Allergy 2011;41:1247-1255
7. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010;8: CD001186
8. Erekosima N, Suarez-Cuervo C, Ramanathan M, Kim JM, Chelladurai Y, Segal JB, Lin SY. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: A systematic review. Laryngoscope 2013. (Epub ahead of print
9. Calamita Z, Saconato H, Bronhara Pelà A, Atallah AN. Efficacy of Sublingual immunotherapy in asthma. Systematic review of randomized clinical trials. Allergy 2006;61:1162-1172
10. Penagos M, Passalacqua G, Compalati E, Tarantini F, Canonica GW. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008;133:599-609
11. Canonica GWeditor. World Allergy Organization position paper on sublingual immunotherapy. Allergy 2009;64:1-59
12. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, Nelson M, Weber R, et al. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol 2011;127:S1-S55
13. Paranos S, Petrovic S. Early effects of rush immunotherapy with Dermatophagoides pteronyssinus in asthmatics. J Investig Allergol Clin Immunol 1997;7:588-595
14. Grembiale RD, Camporota L, Naty S, Tranfa CM, Djukanovic R, Marsico SA. Effects of specific immunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness. Am J Respir Crit Care Med 2000;162:2048-2052
15. Varney VA, Tabbah K, Mavroleon G, Frew AJ. Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: A double-blind, randomized, placebo-controlled trial. Clin Exp Allergy 2003;33:1076-1082
16. Ferrer A, García-Sellés J. Significant improvement in symptoms, skin test, and specific bronchial reactivity after 6 months of treatment with a depigmented, polymerized extract of Dermatophagoides pteronyssinus and D. farinae. J Investig Allergol Clin Immunol 2003;13:244-251
17. Wang H, Lin X, Hao C, Zhang C, Sun B, Zheng J, Chen P, Sheng J, et al. double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy 2006;61: 191-197
18. Tabar AI, Lizaso MT, García BE, Gómez B, Echechipía S, Aldunate MT, Madariaga B, Martínez A, et al. Double-blind, placebo-controlled study of Alternaria alternata immunotherapy: Clinical efficacy and safety. Pediatr Allergy Immunol 2008;19: 67-75
19. Pham-Thi N, Scheinmann P, Fadel R, Combebias A, Andre C. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-Avoidance measures. Pediatr Allergy Immunol 2007;18:47-57
20. Hirsch T, Sahn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite in children. Pediatr Allergy Immunol 1997;8:21-27
21. Dahl R, Stender H, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006;61:185-190
22. Stelmach I, Kaczmarek-Woźniak J, Majak P, Oszlowiek-Chlebna M, Jerzynska A. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Clin Exp Allergy 2009;39:401-408
23. Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009;123:167-173
24. Niu CK, Chen WY, Huang JL, Lue KH, Wang YJ. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: A multi-center, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med 2006;100:1374-1383
25. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: Results of a GA2LEN meta-Analysis. Allergy 2009;64:1570-1579
26. Di Bona D, Plaia A, Scafidi V, Di Lorenzo G. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A systematic review and meta-Analysis. J Allergy Clin Immunol 2010;126:558-566
27. Rak S, Heinrich C, Jacobsen L, Scheynius A, Venge P. A doubleblinded, comparative study of the effects of short preseason specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma. J Allergy Clin Immunol 2001; 108:921-928
28. Shaikh WA. Immunotherapy vs inhaled budesonide in bronchial asthma: An open, parallel, comparative trial. Clin Exp Allergy 1997; 27:1279-1284
29. Pajno GB, Vita D, Parmiani S, Caminiti L, La Grutta S, Barberio G. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp Allergy 2003;33: 1641-1647
30. Marogna M, Spadolini I, Massolo A, Berra D, Zanon P, Chiodini E, Passalacqua G, et al. Long-Term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen. Ann Allergy Asthma Immunol 2009;102:69-75
31. Cox L, Larenas Linneman D, Lockey RF, Passalacqua G. Speaking a common language in immunotherapy. WAO grading of systemic reactions. J Allergy Clin Immunol 2010;125:569-574
32. Passalacqua G, Baena Cagnani C, Bousquet J, Canonica GW, Cox L, Durham S, Durham SR, Larenas-Linnemann D, et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: Speaking the same language. J Allergy Clin Immunol 2013; 132:93-98
33. Lockey RF, Benedicts LM, Turkeltaub PC, Platt-Mills TA. Fatalities from immunotherapy and skin testing. J Allergy Clin Immunol 1987;76:660-677
34. Reid MJ, Lockey RF, Turkeltaub PC, Platt-Mills TA. Survey of fatalities from skin testing and immunotherapy. J Allergy Clin Immunol 1993;92:6-15
35. Bernstein DI, Wanner M, Borish L, Liss GM; Immunotherapy Committee American Academy Allergy Asthma Immunology. Twelve years of survey of fatal reactions to allergen injections and skin testing 1990-2001. J Allergy Clin Immunol 2004;113: 1129-1136
36. Lin MS, Tanner E, Lynn J, Friday GA jr. Non fatal systemic allergic reactions induced by skin test and immunotherapy. Ann Allergy 1993;71:557-562
37. Hetal S, Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006;117:169-175
38. Tinkelman DG, Cole 3rd WQ, Tunno J. Immunotherapy: A one-year prospective study to evaluate risk factors of systemic reactions. J Allergy Clin Immunol 1995;95:8-14
39. Cox L, Jacobsen L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol 2009;103:451-459
40. Baena Cagnani CE, Larenas D, Sisul C, Gomez M, Sanchez Borges M, Canonica GW, Gereda J, Passalacqua G. Allergy training and immunotherapy in Latin America: Results of a regional overview. Ann Allergy Asthma Immunol 2013;111:415-419
41. Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. AAAAI and ACAAI surveillance study of subcutaneous immunotherapy, Year 3: What practices modify the risk of systemic reactions? Ann Allergy Asthma Immunol 2013;110:274-278
42. Committee on the Safety of Medicines. Desensitizing vaccines. BMJ 1989;293:948
43. Ragusa RF, Passalacqua G, Gambardella R, Campanari S, Barbieri MM, Scordamaglia A, Canonica GW. Nonfatal systemic reactions to subcutaneous immunotherapy: A 10 years experience. J Invest Allergol Clin Immunol 1997;7:151-154
44. Moreno C, Cuesta-Herranza J, Fernandez-Tavora L, Alvarez-Cuesta E. Immunotherapy safety: A prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. Clin Exp Allergy 2004;34:527-531
45. Schiappoli M, Ridolo E, Senna G, Alesina R, Antonicelli L, Asero R, Costantino MT, Longo R, et al. A prospective Italian survey on the safety of subcutaneous immunotherapy for respiratory allergy. Clin Exp Allergy 2009;39:1569-1574
46. Rank MA, Oslie CL, Krogman JL, Park MA, Li JT. Allergen immunotherapy safety: Characterizing systemic reactions and identifying risk factors. Allergy Asthma Proc 2008;29:400-405
47. Cox LS, Linnemann DL, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: A comprehensive review. J Allergy Clin Immunol 2006;117:1021-1035
48. Calderón MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: Mode of action and its relationship with the safety profile. Allergy 2012;67: 302-311
49. Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: A randomized, placebo-controlled trial. Allergy 2006;61:181-184
50. Shaaban R, Zureik M, Soussan D, Neukirch C, Heinrich J, Sunyer J, Wjst M, Cerveri I, et al. Rhinitis and onset of asthma: A longitudinal population-based study. Lancet 2008;372:1049-1057
51. Johnstone DE, Dutton A. The value of hyposensitization therapy for bronchial asthma in children-A 14-year study. Pediatrics 1968;42: 793-802
52. Mö ller C, Dreborg S, Ferdousi HA, Halken S, Høst A, Jacobsen L, Koivikko A, Koller DY, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251-256
53. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, Koivikko A, Norberg LA, et al. Specific immunotherapy has long-Term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007;62:943-948
54. Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De marco E, Burastero SE, Calori, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004;114:851-857
55. Marogna M, Tomassetti D, Bernasconi A, Colombo F, Massolo A, Businco A, Canonica GW, Passalacqua G, et al. Preventive effects of sublingual immunotherapy in childhood: An open randomized controlled study. Ann Allergy Asthma Immunol 2008;101: 206-211
56. Brozek JL, Baena Cagnani C, Canonica GW, Bonini S, et al. Methodology for development of the Allergic Rhinitis and its Impact on Asthma guideline 2008 update. Allergy 2008;63:38-46
57. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, Ohta K, et al. Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126:466-470
58. NHLBI Guidelines for the Diagnosis and Treatment of Asthma. www.nhbli.nih.gov/guidelines/asthma
59. Passalacqua G, Canonica GW. Specific immunotherapy: Beyond clinical scores. Ann Allergy Asthma Immunol 2011;107:401-406
60. Peng W, Liu E. Factors influencing the response to specific immunotherapy for asthma in children aged 5-16 years. Pediatr Int 2013. (Epub ahead of print
61. Pajno G, Caminiti L, Vita D, Crisafulli G, Valenzise M, De Luca R, Passalacqua G. Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy. Pediatr Allergy immunol 2011;22:803-807
62. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study. J Allergy Clin Immunol 2010;126:969-975